Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $35.25 billion. The enterprise value is $43.38 billion.
| Market Cap | 35.25B |
| Enterprise Value | 43.38B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Share Statistics
Royalty Pharma has 575.00 million shares outstanding. The number of shares has decreased by -3.88% in one year.
| Current Share Class | 445.28M |
| Shares Outstanding | 575.00M |
| Shares Change (YoY) | -3.88% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 6.12% |
| Owned by Institutions (%) | 84.52% |
| Float | 415.52M |
Valuation Ratios
The trailing PE ratio is 32.89 and the forward PE ratio is 11.37. Royalty Pharma's PEG ratio is 1.41.
| PE Ratio | 32.89 |
| Forward PE | 11.37 |
| PS Ratio | 13.90 |
| Forward PS | 9.85 |
| PB Ratio | 4.00 |
| P/TBV Ratio | 5.97 |
| P/FCF Ratio | 11.84 |
| P/OCF Ratio | 11.84 |
| PEG Ratio | 1.41 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.85, with an EV/FCF ratio of 14.57.
| EV / Earnings | 53.42 |
| EV / Sales | 17.10 |
| EV / EBITDA | 27.85 |
| EV / EBIT | 27.94 |
| EV / FCF | 14.57 |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 0.92.
| Current Ratio | 2.80 |
| Quick Ratio | 2.79 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 5.75 |
| Debt / FCF | 3.01 |
| Interest Coverage | 4.30 |
Financial Efficiency
Return on equity (ROE) is 13.97% and return on invested capital (ROIC) is 5.35%.
| Return on Equity (ROE) | 13.97% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 5.35% |
| Return on Capital Employed (ROCE) | 8.09% |
| Weighted Average Cost of Capital (WACC) | 5.90% |
| Revenue Per Employee | $25.36M |
| Profits Per Employee | $8.12M |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.24% in the last 52 weeks. The beta is 0.43, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +66.24% |
| 50-Day Moving Average | 57.35 |
| 200-Day Moving Average | 48.08 |
| Relative Strength Index (RSI) | 63.43 |
| Average Volume (20 Days) | 2,829,940 |
Short Selling Information
The latest short interest is 10.67 million, so 1.86% of the outstanding shares have been sold short.
| Short Interest | 10.67M |
| Short Previous Month | 12.13M |
| Short % of Shares Out | 1.86% |
| Short % of Float | 2.57% |
| Short Ratio (days to cover) | 3.92 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.54 billion and earned $811.99 million in profits. Earnings per share was $1.86.
| Revenue | 2.54B |
| Gross Profit | 2.43B |
| Operating Income | 1.55B |
| Pretax Income | 1.35B |
| Net Income | 811.99M |
| EBITDA | 1.56B |
| EBIT | 1.55B |
| Earnings Per Share (EPS) | $1.86 |
Balance Sheet
The company has $836.99 million in cash and $8.96 billion in debt, with a net cash position of -$8.12 billion or -$14.13 per share.
| Cash & Cash Equivalents | 836.99M |
| Total Debt | 8.96B |
| Net Cash | -8.12B |
| Net Cash Per Share | -$14.13 |
| Equity (Book Value) | 9.79B |
| Book Value Per Share | 15.33 |
| Working Capital | 1.13B |
Cash Flow
| Operating Cash Flow | 2.98B |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.94M |
| Net Borrowing | 954.48M |
| Free Cash Flow | 2.98B |
| FCF Per Share | $5.18 |
Margins
Gross margin is 95.82%, with operating and profit margins of 61.22% and 32.02%.
| Gross Margin | 95.82% |
| Operating Margin | 61.22% |
| Pretax Margin | 53.11% |
| Profit Margin | 32.02% |
| EBITDA Margin | 61.41% |
| EBIT Margin | 61.22% |
| FCF Margin | 117.37% |
Dividends & Yields
This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 1.53%.
| Dividend Per Share | $0.94 |
| Dividend Yield | 1.53% |
| Dividend Growth (YoY) | 6.32% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 50.42% |
| Buyback Yield | 3.88% |
| Shareholder Yield | 5.42% |
| Earnings Yield | 2.30% |
| FCF Yield | 8.44% |
Analyst Forecast
The average price target for Royalty Pharma is $64.75, which is 5.61% higher than the current price. The consensus rating is "Buy".
| Price Target | $64.75 |
| Price Target Difference | 5.61% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 20.18% |
| EPS Growth Forecast (3Y) | 10.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.73 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.73 |
| Piotroski F-Score | 6 |